Science Impact 2026

Oxcia has been granted Orphan Drug Designation (ODD) by the FDA for OXC-201, its drug candidate for idiopathic pulmonary fibrosis (IPF), just weeks after a similar decision from the EMA.

A Swedish healthcare delegation traveled to Kyiv on September 2–4 to strengthen cooperation on rebuilding Ukraine's healthcare system, timed to one of the most difficult periods for the city in months.

Zealand Pharma has signed an exclusive license agreement with newly formed US biopharmaceutical company Elvinix, granting the rights to develop and commercialize a GLP-1/gastrin dual-agonist peptide portfolio as a regenerative therapy for type 1 diabetes.

The Novo Nordisk Foundation (NNF) and NordForsk have signed a framework agreement to fund Nordic research co-operation over the period 2026–2030.

The US Food and Drug Administration has approved Orexo's Investigational New Drug application for OX640, a needle-free intranasal powder formulation of adrenaline, allowing the company to begin its pivotal clinical development program for the treatment of anaphylaxis.

The funding package consists of equity investments from private investors and significant backing from Business Finland.

ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.